Abstract 1270: The novel PARP1-selective inhibitor, AZD5305, is efficacious as monotherapy and in combination with standard of care chemotherapy in the in vivo preclinical models

Assistant settings

journal：Cancer Research

Authors：Anna D. Staniszewska; James W. Yates JWT; Andy Pike; Christine Fazenbaker; Kimberly Cook; Emily Bosco; Aaron Smith; Joanne Wilson; Elisabetta Leo

Published date：2021-7-1

DOI：10.1158/1538-7445.am2021-1270

PDF link：https://aacrjournals.org/cancerr ... selective-inhibitor

Article link：http://dx.doi.org/10.1158/1538-7445.am2021-1270

Article Source：American Association for Cancer Research (AACR)。


Remark：

This post has been completed

Completed attachments will be deleted within 24 hours.